Quantinno Capital Management LP Purchases 321,824 Shares of Globus Medical, Inc. $GMED

Quantinno Capital Management LP boosted its position in Globus Medical, Inc. (NYSE:GMED) by 142.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 547,095 shares of the medical device company’s stock after buying an additional 321,824 shares during the quarter. Quantinno Capital Management LP’s holdings in Globus Medical were worth $47,138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Advisory Services Network LLC purchased a new position in shares of Globus Medical during the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC increased its holdings in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares during the period. Parallel Advisors LLC raised its stake in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the period. Finally, Headlands Technologies LLC lifted its holdings in Globus Medical by 485.4% during the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 631 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Stock Performance

Shares of GMED opened at $81.32 on Thursday. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The stock’s 50-day simple moving average is $79.73 and its 200 day simple moving average is $85.76. The stock has a market capitalization of $11.04 billion, a price-to-earnings ratio of 18.91, a price-to-earnings-growth ratio of 1.66 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the previous year, the firm earned $0.68 EPS. The company’s quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Activity at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 18.38% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on GMED shares. Truist Financial cut their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Piper Sandler lowered their price target on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research report on Monday, June 15th. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. BMO Capital Markets assumed coverage on shares of Globus Medical in a report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price objective for the company. Finally, UBS Group began coverage on shares of Globus Medical in a research note on Tuesday. They issued a “neutral” rating and a $82.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $102.08.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.